A purine metabolic checkpoint that prevents autoimmunity and autoinflammation.
View / Open Files
Authors
Saveljeva, Svetlana
Sewell, Gavin William
Ramshorn, Katharina
West, James A
Clare, Simon
Haag, Lea-Maxie
de Almeida Rodrigues, Rodrigo Pereira
Unger, Lukas W
Iglesias-Romero, Ana Belén
Holland, Lorraine M
Bourges, Christophe
Md-Ibrahim, Muhammad N
Jones, James Owain
Blumberg, Richard S
Lee, James C
Kaneider, Nicole C
Lawley, Trevor D
Bradley, Allan
Dougan, Gordon
Kaser, Arthur
Publication Date
2022-01-04Journal Title
Cell Metab
ISSN
1550-4131
Publisher
Elsevier BV
Type
Article
This Version
VoR
Metadata
Show full item recordCitation
Saveljeva, S., Sewell, G. W., Ramshorn, K., Cader, M., West, J. A., Clare, S., Haag, L., et al. (2022). A purine metabolic checkpoint that prevents autoimmunity and autoinflammation.. Cell Metab https://doi.org/10.1016/j.cmet.2021.12.009
Abstract
Still's disease, the paradigm of autoinflammation-cum-autoimmunity, predisposes for a cytokine storm with excessive T lymphocyte activation upon viral infection. Loss of function of the purine nucleoside enzyme FAMIN is the sole known cause for monogenic Still's disease. Here we discovered that a FAMIN-enabled purine metabolon in dendritic cells (DCs) restrains CD4+ and CD8+ T cell priming. DCs with absent FAMIN activity prime for enhanced antigen-specific cytotoxicity, IFNγ secretion, and T cell expansion, resulting in excessive influenza A virus-specific responses. Enhanced priming is already manifest with hypomorphic FAMIN-I254V, for which ∼6% of mankind is homozygous. FAMIN controls membrane trafficking and restrains antigen presentation in an NADH/NAD+-dependent manner by balancing flux through adenine-guanine nucleotide interconversion cycles. FAMIN additionally converts hypoxanthine into inosine, which DCs release to dampen T cell activation. Compromised FAMIN consequently enhances immunosurveillance of syngeneic tumors. FAMIN is a biochemical checkpoint that protects against excessive antiviral T cell responses, autoimmunity, and autoinflammation.
Sponsorship
European Research Council (260961)
Wellcome Trust (103077/Z/13/Z)
Wellcome Trust (106260/Z/14/Z)
European Research Council (648889)
Cambridge University Hospitals NHS Foundation Trust (CUH) (BRC)
Academy of Medical Sciences (SGL018/1119)
Wellcome Trust (105920/Z/14/Z)
Wellcome Trust (102163/B/13/Z)
Wellcome Trust (216630/Z/19/Z)
MRC (MC_UU_00014/5)
Identifiers
External DOI: https://doi.org/10.1016/j.cmet.2021.12.009
This record's URL: https://www.repository.cam.ac.uk/handle/1810/331332
Rights
Attribution 4.0 International (CC BY)
Licence URL: http://creativecommons.org/licenses/by/4.0/
Statistics
Total file downloads (since January 2020). For more information on metrics see the
IRUS guide.
Recommended or similar items
The current recommendation prototype on the Apollo Repository will be turned off on 03 February 2023. Although the pilot has been fruitful for both parties, the service provider IKVA is focusing on horizon scanning products and so the recommender service can no longer be supported. We recognise the importance of recommender services in supporting research discovery and are evaluating offerings from other service providers. If you would like to offer feedback on this decision please contact us on: support@repository.cam.ac.uk